Abstract 3430
Background
Immune checkpoint inhibition monotherapy has shown no efficacy in microsatellite-stable (MSS) CRC. Combination strategies are being studied to increase the immunogenicity of this cold tumor. Humanized mice are promising models to evaluate immunotherapy combinations and their effects in the engrafted human immune system.
Methods
3 MSS CRC patient-derived xenografts were injected subcutaneously into 68 mice previously humanized through CD34+ cord blood-derived hematopoietic cell transplantation. Mice were allocated into 4 equivalent groups based on human chimerism detected in the blood and subsequently treated with anti-PD-1 therapy and/or multi-tyrosine kinase inhibition. At harvest, flow cytometry immune data from the lymph nodes (LN), the spleen (SP) and tumor-infiltrating lymphocytes (TIL) were analyzed. Mice were classified according to the specific growth rate (SGR, % volume / day) of their tumor/s into R (under median SGR) vs non-R (over median SGR).
Results
50 mice were considered either R (26) or non-R (24). In the peripheral immune organs (LN and SP), the total number of immune cells was similar between R and non-R mice. However, a higher percentage of human and T cells was found in the SP of R mice. Interestingly, the percentage of B cells was higher in the LN and SP of non-R mice. In contrast, in the tumor, an increased number of human cells (mostly T cells) was found in R mice. Notably, CD8+ T cells were significantly higher among TILs. A linear regression analysis was performed, and the number of human and T (CD4+ and CD8+) cells in the tumor significantly decreased (P<.001for all of them) with an increasing tumor SGR.Table: 1904P
Periphery % cells | Tumor nº cells / g | ||||||||
---|---|---|---|---|---|---|---|---|---|
LN | SP | R | Non-R | P* | |||||
R | Non-R | P | R | Non-R | P | ||||
Human cells T cells CD4 CD8 B cells | 95 78 77 23 10 | 94 76 79 20 16 | .17 .40 .54 .51 .016 | 38 81 77 23 10 | 23 71 75 24 21 | .009 .017 .68 .72 .001 | 57648 47794 38094 9210 443 | 22745 18191 14852 3052 555 | .036 .052 .069 .012 .079 |
T-test on Ln-transformed values
Conclusions
Different immune responses were observed both in the periphery and in the tumor between R and non-R mice. The humanized mouse model appears to be a valid model to evaluate immunotherapy combinations for MSS CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Colorado, Anschutz Medical Campus.
Funding
University of Colorado, Anschutz Medical Campus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract